Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Recommendation of “Hold” by Analysts

Valneva SE Sponsored ADR (NASDAQ:VALN) has received a consensus recommendation of “Hold” from the five ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $11.9750.

A number of research firms recently commented on VALN. Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st. The Goldman Sachs Group cut Valneva from a “neutral” rating to a “sell” rating and set a $4.90 target price on the stock. in a research report on Wednesday, April 22nd. Guggenheim set a $11.00 price target on Valneva in a research note on Thursday, April 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a research report on Thursday, June 18th.

Valneva Stock Performance

NASDAQ:VALN opened at $5.22 on Monday. The company has a current ratio of 2.14, a quick ratio of 1.60 and a debt-to-equity ratio of 2.14. Valneva has a 12 month low of $5.04 and a 12 month high of $12.25. The company has a market cap of $495.33 million, a PE ratio of -2.79 and a beta of 1.77. The company has a 50 day simple moving average of $5.57 and a two-hundred day simple moving average of $7.75.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. The firm had revenue of $35.77 million for the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. Research analysts forecast that Valneva will post -1 earnings per share for the current year.

Institutional Trading of Valneva

Large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new stake in Valneva during the fourth quarter valued at approximately $94,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Valneva during the 4th quarter worth $44,000. JPMorgan Chase & Co. purchased a new position in shares of Valneva during the 3rd quarter worth $124,000. VSM Wealth Advisory LLC grew its position in shares of Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after acquiring an additional 5,000 shares during the period. Finally, Marex Group plc bought a new stake in shares of Valneva during the 2nd quarter valued at $64,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.